9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Estimated reading time: < 1 min

Condition: Cervical Cancer

Estimated Enrollment: 41

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Number of treatment-emergent adverse events,  Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only),  Cmax of INCAGN02390, Tmax of INCAGN02390

Interventions: INCAGN02390,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: January 2020

Completion Date: June 2020

Last  Posted Date: August 1, 2019

Location: The Angeles Clinical and Research Institute, Los Angeles, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03652077

Was this article helpful?
Dislike 0